Embecta (NASDAQ:EMBC) Issues FY 2026 Earnings Guidance

Embecta (NASDAQ:EMBC) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.550-1.75 for the period, compared to the consensus earnings per share estimate of 2.820. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.1 billion.

Embecta Trading Down 55.0%

EMBC stock traded down $5.09 during mid-day trading on Tuesday, reaching $4.17. The company’s stock had a trading volume of 8,267,536 shares, compared to its average volume of 881,754. Embecta has a 12 month low of $4.02 and a 12 month high of $15.55. The business’s 50 day moving average price is $9.26 and its 200 day moving average price is $11.27. The company has a market cap of $246.65 million, a price-to-earnings ratio of 1.76 and a beta of 1.09.

Embecta (NASDAQ:EMBC) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.15). The company had revenue of $221.80 million for the quarter, compared to analyst estimates of $235.67 million. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The business’s quarterly revenue was down 14.4% compared to the same quarter last year. During the same period last year, the business earned $0.70 EPS. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. As a group, equities analysts expect that Embecta will post 2.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Wall Street Zen raised shares of Embecta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. BTIG Research reissued a “buy” rating and issued a $25.00 price objective on shares of Embecta in a research note on Friday, February 6th. Mizuho lowered their target price on Embecta from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Monday, April 13th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Embecta has a consensus rating of “Hold” and a consensus target price of $18.50.

Institutional Trading of Embecta

Several institutional investors and hedge funds have recently modified their holdings of EMBC. Larson Financial Group LLC boosted its position in shares of Embecta by 368.6% during the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after buying an additional 1,574 shares during the last quarter. Wexford Capital LP bought a new position in Embecta during the 3rd quarter valued at $94,000. Tower Research Capital LLC TRC lifted its stake in Embecta by 542.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after acquiring an additional 6,224 shares in the last quarter. iSAM Funds UK Ltd purchased a new position in Embecta during the 3rd quarter worth $115,000. Finally, Amundi bought a new stake in shares of Embecta in the 4th quarter worth $127,000. 93.83% of the stock is owned by hedge funds and other institutional investors.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.